Background Approximately 50 000 influenza-associated deaths occur annually in the United
States, overwhelmingly among individuals aged≥ 65 years. Although vaccination is the …

Background Studies among individuals ages≥ 65 years have found a moderately higher
relative vaccine effectiveness (RVE) for the high-dose (HD) influenza vaccine compared with …

Background The low influenza vaccine effectiveness (VE) observed during the A (H3N2)-
dominated 2017–2018 season may be due to vaccine virus adaptation to growth in eggs …

The influenza-related disease burden is highest among the elderly. We evaluated the
relative vaccine effectiveness (rVE) of adjuvanted trivalent influenza vaccine (aTIV) …

Background We examined whether a high-dose inactivated influenza vaccine was more
efficacious in preventing hospitalizations than a standard-dose vaccine in the Veterans …

Background Adults 65 years and older (seniors) experience more complications following
influenza infection than younger adults. We estimated the relative vaccine effectiveness …

Background The effectiveness of standard, egg-derived quadrivalent influenza vaccines
(IIV4) may be reduced in adults≥ 65 years of age, largely because of immunosenescence …

Background Seasonal influenza causes substantial morbidity and mortality in older adults.
High-dose inactivated influenza vaccine (HD-IIV), with increased antigen content compared …

Background. Recipients of high-dose vs standard-dose influenza vaccines have fewer
influenza illnesses. We evaluated the comparative effectiveness of high-dose vaccine in …

Background A high-dose trivalent inactivated influenza vaccine was licensed in 2009 by the
US Food and Drug Administration (FDA) on the basis of serological criteria. We sought to …